查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856986

全球表觀遺傳診斷市場：預測至 2032 年—按產品、診斷方法、技術、應用、最終用戶和地區分類的分析

Epigenetics Diagnostics Market Forecasts to 2032 - Global Analysis By Product (Reagents, Kits, Instruments, Enzymes, Software & Bioinformatics Tools and Services), Diagnostic, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球表觀遺傳診斷市場規模將達到 196.1 億美元，到 2032 年將達到 606.4 億美元，預測期內複合年成長率為 17.5%。

表觀遺傳診斷是指研究和分析基因表現中可遺傳的變化，這些變化不涉及DNA序列本身的改變，而是由DNA甲基化、組蛋白修飾和非編碼RNA活性等化學修飾引起的。這些診斷工具有助於檢測影響基因活性的疾病特異性表觀遺傳模式，尤其是在癌症、神經系統疾病、心血管疾病和自體免疫疾病。識別這些表觀遺傳生物標記可以為臨床醫生提供疾病機制、預後和治療反應的寶貴見解。表觀遺傳診斷在個人化醫療中發揮關鍵作用，透過早期檢測、標靶治療和精準醫療，能夠改善患者的治療效果。

據世界衛生組織稱，預計到 2050 年，新增癌症病例將超過 3,500 萬例，比 2022 年大幅增加 77%。

癌症和慢性病負擔日益加重

表觀遺傳生物標記，例如DNA甲基化、組蛋白修飾和非編碼RNA表達，能夠實現疾病的早期檢測和分層。診斷平台支援對高發病率進行非侵入性篩檢、風險評估和治療監測。與液態切片和多組體學工作流程的整合可提高臨床效用並改善患者預後。隨著公共衛生計畫和個人化醫療計畫的推進，對精準診斷的需求日益成長。這一趨勢正在推動慢性病管理和分子病理學領域平台的擴展。

設備和診斷檢測高成本

表觀遺傳學分析需要定序儀、微陣列和質譜系統等專用設備，導致高昂的購買成本和營運成本。試劑、試劑盒和樣本製備流程也增加了每次檢測的成本和工作流程的複雜性。小型實驗室和資源有限的研究機構在沒有外部資金或報銷支持的情況下，難以採用先進的表觀遺傳學平台。缺乏經濟高效的標準化檢測方法阻礙了其在常規臨床應用和人群篩檢中的推廣。這些限制因素持續阻礙分散式、預算敏感的醫療機構採用表觀遺傳學分析技術。

定序的進步和成本的降低

新一代定序平台支援對甲基化模式、染色質可及性和轉錄組譜進行高通量分析。自動化、多重定序和試劑最佳化正在降低每個鹼基的成本並縮短週轉時間。與雲端基礎的生物資訊學和人工智慧主導的解讀相結合，提高了不同樣本類型的可擴展性和可重複性。腫瘤臨床試驗、罕見疾病研究和群體基因組學領域對全面且經濟的表觀遺傳分析的需求日益成長。這些趨勢正在推動定序診斷平台和服務模式的整體發展。

監管和報銷方面的不確定性

生物標記合格、分析驗證和臨床效用論證的監管要求各不相同。缺乏統一的標準和性能基準，使得核准和醫保參與變得複雜。公共和私人醫保機構對表觀遺傳學檢測的報銷途徑仍不完善，尤其是對於新興生物標記和多組體學檢測。診斷試劑開發商在應對複雜的監管環境和證明其在各種醫療保健系統中的成本效益方面面臨許多挑戰。這些風險持續限制全球市場的商業化和臨床應用。

新冠疫情的影響：

疫情導致的停工、供應鏈中斷和資源重新分配擾亂了診斷流程和研究項目。然而，隨著各公司對新冠肺炎患者的免疫反應、病毒持續存在和長期後遺症進行研究，人們對錶觀遺傳生物標記的興趣日益濃厚。對液態切片、遠端採樣和數位病理學的投資加速了平台創新和部署。消費者和臨床領域對分子診斷和個人化醫療的認知度均有所提升。後疫情時代的策略已將表觀遺傳學作為疾病監測、風險分層和標靶治療的核心支柱。這種轉變正在加強對錶觀遺傳學基礎設施和轉化研究的長期投資。

預計在預測期內，DNA甲基化分析領域將成為最大的細分市場。

由於其臨床相關性、檢測技術的成熟度和在多種疾病領域的廣泛適用性，預計在預測期內，DNA甲基化分析領域將佔據最大的市場佔有率。甲基化生物標記有助於癌症、神經退化疾病和自體免疫疾病的早期檢測、預後評估和治療監測。相關平台採用亞硫酸氫鹽定序、甲基化晶片和標靶PCR等技術，以高靈敏度和特異性定量分析甲基化變化。與液態切片和人工智慧輔助解讀相結合，可增強非侵入性篩檢和長期追蹤。醫院、研究機構和診斷實驗室對檢驗且可擴展的甲基化檢測方法的需求日益成長。

預計在預測期內，軟體和生物資訊學工具細分市場將以最高的複合年成長率成長。

在預測期內，軟體和生物資訊學工具領域預計將呈現最高的成長率，因為數據複雜性和多體學整合推動了對高階分析的需求。平台支援對甲基化、組蛋白和轉錄組層面的表觀遺傳資料集進行預處理、標準化和統計建模。人工智慧和機器學習演算法能夠實現跨臨床隊列的生物標記發現、疾病分類和預測建模。基於雲端基礎的基礎設施和模組化流程提高了實驗室和醫院的可擴展性和可訪問性。在診斷和轉化研究領域，對可互通、安全且經過臨床檢驗的生物資訊工具的互通性日益成長。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療基礎設施、充足的研究經費以及在分子診斷領域的監管參與。美國和加拿大的研究機構正在部署表觀遺傳學平台，將定序和生物資訊學工作流程整合到腫瘤學、神經病學和罕見疾病計畫中。對精準醫療、產學研合作以及臨床試驗網路的投資，為這些平台的擴充性和檢驗提供了支持。大型診斷公司、研究中心和監管機構的存在，正在推動技術創新和標準化。這些因素共同促成了北美在表觀遺傳學診斷和轉化醫學領域的領先地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率，這主要得益於醫療現代化、癌症負擔加重以及基因組醫學計劃在區域經濟中的融合。中國、印度、日本和韓國等國家正在公共衛生計畫、學術研究和臨床診斷領域推廣表觀遺傳學平台。政府支持的舉措正在推動基礎設施建設、新創公司孵化以及生物標記發現和檢測方法檢驗的國際合作。新興企業企業提供經濟高效且符合當地實際情況的解決方案，以滿足疾病特徵和合規性需求。這些趨勢正在推動該地區表觀遺傳學診斷和個人化醫療生態系統的發展。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

5. 全球表觀遺傳學診斷市場（按產品分類）

  • 試劑
  • 成套工具
  • 裝置
  • 酵素
  • 軟體和生物資訊學工具
  • 服務

6. 全球表觀遺傳學診斷市場（依診斷方式分類）

  • DNA甲基化
  • 組蛋白修飾
  • 微型RNA譜分析
  • 染色質免疫沉澱分析法（ChIP）
  • 其他診斷

7. 全球表觀遺傳學診斷市場（依技術分類）

  • DNA甲基化分析
  • 組蛋白修飾譜分析
  • 微型RNA表現分析
  • 染色質可及性分析
  • 次世代定序（NGS）
  • 基於PCR的表觀遺傳學工具
  • 其他技術

8. 全球表觀遺傳學診斷市場（按應用分類）

  • 瘤
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌
  • 非腫瘤
    • 自體免疫疾病
    • 神經系統疾病
    • 代謝紊亂
    • 心血管疾病
    • 感染疾病

9. 全球表觀遺傳診斷市場（依最終用戶分類）

  • 醫院和診所
  • 診斷實驗室
  • 製藥和生物技術公司
  • 學術和研究機構
  • 其他最終用戶

第10章 全球表觀遺傳學診斷市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Illumina
  • Thermo Fisher Scientific
  • Cantata Bio
  • Bio-Rad Laboratories
  • PerkinElmer
  • Qiagen
  • Active Motif
  • Zymo Research
  • Abcam
  • Diagenode
  • EpiGentek Group Inc.
  • New England Biolabs
  • Merck KGaA
  • GenScript Biotech
  • Creative Biolabs
Product Code: SMRC31851

According to Stratistics MRC, the Global Epigenetics Diagnostics Market is accounted for $19.61 billion in 2025 and is expected to reach $60.64 billion by 2032 growing at a CAGR of 17.5% during the forecast period. Epigenetics diagnostics refers to the study and analysis of heritable changes in gene expression that do not involve alterations in the DNA sequence itself but are caused by chemical modifications such as DNA methylation, histone modification, and non-coding RNA activity. These diagnostic tools help detect disease-specific epigenetic patterns that influence gene activity, particularly in cancer, neurological, cardiovascular, and autoimmune disorders. By identifying these epigenetic biomarkers, clinicians can gain valuable insights into disease mechanisms, prognosis, and response to therapy. Epigenetics diagnostics plays a crucial role in personalized medicine, enabling early detection, targeted treatment, and improved patient outcomes through precision healthcare.

According to the WHO, over 35 million new cancer cases are expected in 2050, marking a significant 77% increase from in 2022.

Market Dynamics:

Driver:

Rising cancer & chronic-disease burden

Epigenetic biomarkers such as DNA methylation, histone modification, and non-coding RNA expression enable early detection and disease stratification. Diagnostic platforms support non-invasive screening, risk profiling, and treatment monitoring across high-incidence conditions. Integration with liquid biopsy and multi-omics workflows enhances clinical utility and patient outcomes. Demand for precision diagnostics is rising across public health programs and personalized medicine initiatives. These dynamics are propelling platform expansion across chronic disease management and molecular pathology.

Restraint:

High cost of instruments and diagnostic assays

Epigenetic analysis requires specialized equipment such as sequencers, microarrays, and mass spectrometry systems with high capital and operational expenditure. Reagents, kits, and sample preparation protocols add to per-test cost and workflow complexity. Smaller labs and resource-constrained institutions face challenges in adopting advanced epigenetic platforms without external funding or reimbursement support. Lack of cost-effective and standardized assays hampers routine clinical use and population-scale screening. These constraints continue to hinder adoption across decentralized and budget-sensitive healthcare settings.

Opportunity:

Advances and lower cost in sequencing

Next-generation sequencing platforms support high-throughput analysis of methylation patterns, chromatin accessibility, and transcriptomic profiles. Cost per base and turnaround time are declining due to automation, multiplexing, and reagent optimization. Integration with cloud-based bioinformatics and AI-driven interpretation improves scalability and reproducibility across diverse sample types. Demand for comprehensive and affordable epigenetic profiling is rising across oncology trials, rare disease research, and population genomics. These trends are fostering growth across sequencing-enabled diagnostic platforms and service models.

Threat:

Regulatory & reimbursement uncertainty

Regulatory bodies vary in their requirements for biomarker qualification, analytical validation, and clinical utility demonstration. Lack of harmonized standards and performance benchmarks complicates approval and payer engagement. Reimbursement pathways for epigenetic tests remain underdeveloped across public and private insurers, especially for emerging biomarkers and multi-omics panels. Diagnostic developers face challenges in navigating regulatory landscapes and demonstrating cost-effectiveness across diverse healthcare systems. These risks continue to constrain commercialization and clinical integration across global markets.

Covid-19 Impact:

The pandemic disrupted diagnostic workflows and research programs due to lockdowns, supply chain interruptions, and resource reallocation. However, interest in epigenetic biomarkers surged as researchers explored immune response, viral persistence, and long-term sequelae across COVID-19 patients. Investment in liquid biopsy, remote sampling, and digital pathology accelerated platform innovation and deployment. Public awareness of molecular diagnostics and personalized medicine increased across consumer and clinical segments. Post-pandemic strategies now include epigenetics as a core pillar of disease surveillance, risk stratification, and therapeutic targeting. These shifts are reinforcing long-term investment in epigenetic infrastructure and translational research.

The DNA methylation analysis segment is expected to be the largest during the forecast period

The DNA methylation analysis segment is expected to account for the largest market share during the forecast period due to its clinical relevance, assay maturity, and broad applicability across disease areas. Methylation biomarkers support early detection, prognosis, and treatment monitoring across cancer, neurodegeneration, and autoimmune disorders. Platforms use bisulfite sequencing, methylation arrays, and targeted PCR to quantify methylation changes with high sensitivity and specificity. Integration with liquid biopsy and AI-driven interpretation enhances non-invasive screening and longitudinal tracking. Demand for validated and scalable methylation assays is rising across hospitals, research institutions, and diagnostic labs.

The software & bioinformatics tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the software & bioinformatics tools segment is predicted to witness the highest growth rate as data complexity and multi-omics integration drive demand for advanced analytics. Platforms support preprocessing, normalization, and statistical modeling of epigenetic datasets across methylation, histone, and transcriptomic layers. AI and machine learning algorithms enable biomarker discovery, disease classification, and predictive modeling across clinical cohorts. Cloud-based infrastructure and modular pipelines improve scalability and accessibility across labs and hospitals. Demand for interoperable, secure, and clinically validated bioinformatics tools is rising across diagnostics and translational research.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced healthcare infrastructure, research funding, and regulatory engagement across molecular diagnostics. U.S. and Canadian institutions deploy epigenetic platforms across oncology, neurology, and rare disease programs with integrated sequencing and bioinformatics workflows. Investment in precision medicine, academic-industry partnerships, and clinical trial networks supports platform scalability and validation. Presence of leading diagnostic firms, research centres, and regulatory bodies drives innovation and standardization. These factors are propelling North America's leadership in epigenetic diagnostics and translational medicine.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, cancer burden, and genomic medicine initiatives converge across regional economies. Countries like China, India, Japan, and South Korea scale epigenetic platforms across public health programs, academic research, and clinical diagnostics. Government-backed initiatives support infrastructure development, startup incubation, and international collaboration across biomarker discovery and assay validation. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. These trends are accelerating regional growth across epigenetic diagnostics and personalized medicine ecosystems.

Key players in the market

Some of the key players in Epigenetics Diagnostics Market include Illumina, Thermo Fisher Scientific, Cantata Bio, Bio-Rad Laboratories, PerkinElmer, Qiagen, Active Motif, Zymo Research, Abcam, Diagenode, EpiGentek Group Inc., New England Biolabs, Merck KGaA, GenScript Biotech and Creative Biolabs.

Key Developments:

In June 2025, Thermo Fisher launched an upgraded Applied Biosystems(TM) Methyl-Seq workflow, integrating automated bisulfite conversion and AI-powered methylation analysis. The platform supports early cancer detection and epigenetic biomarker discovery across oncology and rare disease applications.

In June 2025, Illumina introduced enhanced epigenetic sequencing workflows integrated with its NovaSeq X Plus platform, supporting high-throughput analysis of DNA methylation and histone modifications. The update enables early cancer detection and precision diagnostics across oncology and rare diseases. It aligns with Illumina's push toward multi-omic profiling and AI-powered biomarker discovery.

Products Covered:

  • Reagents
  • Kits
  • Instruments
  • Enzymes
  • Software & Bioinformatics Tools
  • Services

Diagnostics Covered:

  • DNA Methylation
  • Histone Modification
  • MicroRNA Profiling
  • Chromatin Immunoprecipitation (ChIP)
  • Other Diagnostics

Technologies Covered:

  • DNA Methylation Analysis
  • Histone Modification Profiling
  • MicroRNA Expression Analysis
  • Chromatin Accessibility Assays
  • Next-Generation Sequencing (NGS)
  • PCR-Based Epigenetic Tools
  • Other Technologies

Applications Covered:

  • Oncology
  • Non-Oncology

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epigenetics Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents
  • 5.3 Kits
  • 5.4 Instruments
  • 5.5 Enzymes
  • 5.6 Software & Bioinformatics Tools
  • 5.7 Services

6 Global Epigenetics Diagnostics Market, By Diagnostic

  • 6.1 Introduction
  • 6.2 DNA Methylation
  • 6.3 Histone Modification
  • 6.4 MicroRNA Profiling
  • 6.5 Chromatin Immunoprecipitation (ChIP)
  • 6.6 Other Diagnostics

7 Global Epigenetics Diagnostics Market, By Technology

  • 7.1 Introduction
  • 7.2 DNA Methylation Analysis
  • 7.3 Histone Modification Profiling
  • 7.4 MicroRNA Expression Analysis
  • 7.5 Chromatin Accessibility Assays
  • 7.6 Next-Generation Sequencing (NGS)
  • 7.7 PCR-Based Epigenetic Tools
  • 7.8 Other Technologies

8 Global Epigenetics Diagnostics Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology
    • 8.2.1 Breast Cancer
    • 8.2.2 Lung Cancer
    • 8.2.3 Colorectal Cancer
    • 8.2.4 Prostate Cancer
  • 8.3 Non-Oncology
    • 8.3.1 Autoimmune Disorders
    • 8.3.2 Neurological Disorders
    • 8.3.3 Metabolic Disorders
    • 8.3.4 Cardiovascular Diseases
    • 8.3.5 Infectious Diseases

9 Global Epigenetics Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Academic & Research Institutions
  • 9.6 Other End Users

10 Global Epigenetics Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Illumina
  • 12.2 Thermo Fisher Scientific
  • 12.3 Cantata Bio
  • 12.4 Bio-Rad Laboratories
  • 12.5 PerkinElmer
  • 12.6 Qiagen
  • 12.7 Active Motif
  • 12.8 Zymo Research
  • 12.9 Abcam
  • 12.10 Diagenode
  • 12.11 EpiGentek Group Inc.
  • 12.12 New England Biolabs
  • 12.13 Merck KGaA
  • 12.14 GenScript Biotech
  • 12.15 Creative Biolabs

List of Tables

  • Table 1 Global Epigenetics Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Epigenetics Diagnostics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Epigenetics Diagnostics Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 4 Global Epigenetics Diagnostics Market Outlook, By Kits (2024-2032) ($MN)
  • Table 5 Global Epigenetics Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 6 Global Epigenetics Diagnostics Market Outlook, By Enzymes (2024-2032) ($MN)
  • Table 7 Global Epigenetics Diagnostics Market Outlook, By Software & Bioinformatics Tools (2024-2032) ($MN)
  • Table 8 Global Epigenetics Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 9 Global Epigenetics Diagnostics Market Outlook, By Diagnostic (2024-2032) ($MN)
  • Table 10 Global Epigenetics Diagnostics Market Outlook, By DNA Methylation (2024-2032) ($MN)
  • Table 11 Global Epigenetics Diagnostics Market Outlook, By Histone Modification (2024-2032) ($MN)
  • Table 12 Global Epigenetics Diagnostics Market Outlook, By MicroRNA Profiling (2024-2032) ($MN)
  • Table 13 Global Epigenetics Diagnostics Market Outlook, By Chromatin Immunoprecipitation (ChIP) (2024-2032) ($MN)
  • Table 14 Global Epigenetics Diagnostics Market Outlook, By Other Diagnostics (2024-2032) ($MN)
  • Table 15 Global Epigenetics Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 16 Global Epigenetics Diagnostics Market Outlook, By DNA Methylation Analysis (2024-2032) ($MN)
  • Table 17 Global Epigenetics Diagnostics Market Outlook, By Histone Modification Profiling (2024-2032) ($MN)
  • Table 18 Global Epigenetics Diagnostics Market Outlook, By MicroRNA Expression Analysis (2024-2032) ($MN)
  • Table 19 Global Epigenetics Diagnostics Market Outlook, By Chromatin Accessibility Assays (2024-2032) ($MN)
  • Table 20 Global Epigenetics Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 21 Global Epigenetics Diagnostics Market Outlook, By PCR-Based Epigenetic Tools (2024-2032) ($MN)
  • Table 22 Global Epigenetics Diagnostics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 23 Global Epigenetics Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Epigenetics Diagnostics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 25 Global Epigenetics Diagnostics Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 26 Global Epigenetics Diagnostics Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 27 Global Epigenetics Diagnostics Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 28 Global Epigenetics Diagnostics Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 29 Global Epigenetics Diagnostics Market Outlook, By Non-Oncology (2024-2032) ($MN)
  • Table 30 Global Epigenetics Diagnostics Market Outlook, By Autoimmune Disorders (2024-2032) ($MN)
  • Table 31 Global Epigenetics Diagnostics Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 32 Global Epigenetics Diagnostics Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
  • Table 33 Global Epigenetics Diagnostics Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 34 Global Epigenetics Diagnostics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 35 Global Epigenetics Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 36 Global Epigenetics Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 37 Global Epigenetics Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 38 Global Epigenetics Diagnostics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 39 Global Epigenetics Diagnostics Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)
  • Table 40 Global Epigenetics Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.